Eisai's Halaven Wins Approval In Liposarcoma
This article was originally published in Scrip
Executive Summary
The FDA on Jan. 28 gave its blessing to Eisai Co. Ltd. to market Halaven (eribulin mesylate), a microtubule dynamics inhibitor, to treat advanced or unresectable liposarcoma, a specific type of soft tissue sarcoma, in patients who received prior anthracycline-containing chemotherapy.